Raynaud’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Raynaud's disease or Raynaud's phenomenon (RP) manifests as a vascular disorder marked by periodic episodes of a three-phase color reaction in the digits and occasionally in the ears or nose. In medical literature, RP often denotes the idiopathic form of the condition. The diagnosis and classification of the Raynaud phenomenon have become more manageable in recent times. Thorough clinical history-taking, physical examination, and specific tests aid in accurate diagnosis, distinguishing between primary and secondary forms. Utilizing all available information and the latest investigative tools is crucial. This approach facilitates early detection of underlying medical issues and offers reassurance to patients with primary Raynaud phenomenon. Primary Raynaud phenomenon typically presents with mild symptoms, symmetric involvement, and laboratory findings, often requiring no medication. Conversely, features suggestive of secondary Raynaud syndrome include painful attacks, digital ulcers, asymmetric symptoms, positive autoantibody tests, abnormal nail-fold capillaries, and elevated inflammatory markers. Treatment strategies for Raynaud phenomenon should be tailored to individual patients based on their clinical presentation. Initial management involves cold avoidance and wearing warm, layered clothing. Vasodilators, such as calcium channel blockers or topical nitroprusside, are prescribed for moderate to severe cases. Additionally, medications like iloprost and sildenafil have shown efficacy, particularly in systemic sclerosis patients with severe ischemic ulcers associated with the Raynaud phenomenon.
- In systemic sclerosis, Raynaud's phenomenon is prevalent, occurring in 80% to 90% of patients, and it can even be the initial symptom in around 33% of cases.
Thelansis’s “Raynaud’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Raynaud’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Raynaud’s Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Raynaud’s Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment